# A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors

Source: https://onco.cc/trials/nct07126665/  
OnCo record `nct07126665` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of QLC5508 in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.

## Summary

A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT07126665 by Minghui Pharmaceutical (Hangzhou) Ltd, with 116 participants planned, started 2025-09-18 and due to reach its primary completion in 2029-08. Interventions recorded: MHB088C for Injection and MHB039A for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07126665
- Phase: 1/2
- Setting: An Open-label Phase I/II Clinical Study of MHB088C for Injection Combined With MHB039A for Injection in Patients With Advanced Malignant Solid Tumors
- Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd
- Enrolled: 116

## Sources

- ClinicalTrials.gov NCT07126665: https://clinicaltrials.gov/study/NCT07126665

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [MHB039A](https://onco.cc/drugs/mhb039a/), [QLC5508](https://onco.cc/drugs/qlc5508/)

---
JSON: https://onco.cc/api/v1/entities/nct07126665.json